NovaBay Pharmaceuticals Appoints Justin Hall President and CEO, and Jason Raleigh CFO
June 17 2019 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
biopharmaceutical company focusing on commercializing Avenova® for
the domestic eye care market, announces the appointments of Justin
Hall as President and Chief Executive Officer, and Jason Raleigh as
Chief Financial Officer. Hall has served as interim President and
CEO, and Raleigh as interim CFO since March 2019.
“Justin and Jason have proven their leadership abilities by
successfully implementing the shift in our U.S. commercial strategy
we announced in March and executing the recent launch of our U.S.
direct-to-consumer sales of Avenova on Amazon.com,” said Paul E.
Freiman, Chairman of NovaBay.
“This is a very exciting time at NovaBay as we launch Avenova
Direct, making our leading lid and lash spray directly accessible
to consumers without a prescription and at affordable pricing,”
said Hall. “My close working relationships with our Board,
principal investors, and sales force are key to quickly adjusting
our strategy to rapidly address opportunities in the marketplace.
We are on the move and we have momentum.”
The Avenova Direct page on Amazon.com is available here.
“I’m honored to be selected as CFO and appreciate the Board’s
trust in my abilities,” said Raleigh. “I look forward to continuing
to work with Justin and the NovaBay team toward the continued
successful commercialization of Avenova.”
Hall has served with NovaBay for six years in a variety of roles
including as corporate counsel and has been actively involved in a
number of operating functions including the sales organization and
manufacturing. Raleigh has been with NovaBay for more than three
years and has nearly 20 years of financial experience.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our future momentum and online
sales, Board and executive composition, and generally the company’s
expected future financial results. These statements involve known
and unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to our ability to remain a publicly listed
company, maintain the support of our majority shareholders, and
ability to adhere to our approved NYSE compliance plan. Other risks
relating to NovaBay’s business, including risks that could cause
results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on NovaBay’s progress:Like us
on FacebookFollow us on TwitterConnect with NovaBay
on LinkedInVisit NovaBay’s Website
Avenova Purchasing InformationFor NovaBay Avenova
purchasing information:Please call 800-890-0329 or
email sales@avenova.com.www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190617005205/en/
NovaBay ContactJustin HallPresident and Chief Executive
Officer510-899-8800jhall@novabay.com
Investor ContactLHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024